Online inquiry

IVTScrip™ mRNA-Anti-PDCD1, AGEN2034(Cap 1, 5-Methyl-CTP, 30 nt-poly(A))   (CAT#: GTTS-WQ1906MR)

This product GTTS-WQ1906MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 1 & 5-Methyl-CTP. It ecodes the monoclonal antibody that targets PDCD1 gene. The antibody can be applied in Cervical Cancer research.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP
5' Cap Cap 1
Species Homo sapiens
RefSeq NM_005018.3
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 5133
UniProt ID Q15116
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-PDCD1, AGEN2034(Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) (GTTS-WQ1906MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ3654MR IVTScrip™ mRNA-Anti-FGFR2, BAY 1187982(Cap 1, Pseudo-UTP, 120 nt-poly(A)) mRNA BAY 1187982
GTTS-WQ14650MR IVTScrip™ mRNA-Anti-DLL3, SC0001-SCX(Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) mRNA SC0001-SCX
GTTS-WQ7670MR IVTScrip™ mRNA-Anti-CD3E&MS4A1, GEN3013(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA GEN3013
GTTS-WQ2442MR IVTScrip™ mRNA-Anti-TSLP, AMG 157(Cap 1, Pseudo-UTP, 120 nt-poly(A)) mRNA AMG 157
GTTS-WQ482MR IVTScrip™ mRNA-Anti-SELP, 42-89-glycoprotein(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA 42-89-glycoprotein
GTTS-WQ6897MR IVTScrip™ mRNA-Anti-CX3CL1, E-6011(Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) mRNA E-6011
GTTS-WQ35MR IVTScrip™ mRNA-Anti-TNFRSF17, 2857916(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA 2857916
GTTS-WQ14127MR IVTScrip™ mRNA-Anti-PCSK9, aPCSK927(Cap 0, Pseudo-UTP, 120 nt-poly(A)) mRNA aPCSK927
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW